

Review

# Mitochondrial dynamics in stem cells and differentiation

Bong Jong Seo<sup>1,2</sup>, Sang Hoon Yoon<sup>1,2</sup> and Jeong Tae Do<sup>1,\*</sup>

<sup>1</sup> Department of Stem Cell and Regenerative Biotechnology, Konkuk Institute of Technology, Konkuk University, Seoul, Republic of Korea

<sup>2</sup> These authors contributed equally to this work.

\* Correspondence: [dojt@konkuk.ac.kr](mailto:dojt@konkuk.ac.kr); Tel.: +82-2-450-3673

**Abstract:** Mitochondria are highly dynamic organelles that continuously change their shape. Their main function is ATP production; however, they are additionally involved in a variety of cellular phenomena, such as apoptosis, cell cycle, proliferation, differentiation, reprogramming, and aging. The change in mitochondrial morphology is closely related to the functionality of mitochondria. Normal mitochondrial dynamics are critical for cellular function, embryonic development, and tissue formation. Thus, defect in proteins involved in mitochondrial dynamics that control mitochondrial fusion and fission can affect cellular differentiation, proliferation, cellular reprogramming, and aging. Here we review the processes and proteins involved in mitochondrial dynamics and its various associated cellular phenomena.

**Keywords:** Mitochondria; Mitochondrial dynamics; fusion; fission; pluripotency; differentiation


## 1. Introduction

Mitochondria are cytoplasmic organelles of cells and function as energy stations for adenosine triphosphate (ATP) production. The major functions of mitochondria are aerobic energy production, ROS production, calcium homeostasis, cellular signaling pathways, and synthesis and/or assembly of cellular metabolites, such as fatty acids, amino acids, iron/sulfur clusters, pyrimidines, heme, and steroid hormones [7–9]. Mitochondrial dysfunction causes aging, loss of synaptic nerve cells, and cell death in many human neurological diseases [10, 11]. The shape of a mitochondrion is directly or indirectly determined by several factors. The indirect determinants of mitochondrial shape include several environmental conditions such as a low-oxygen [1], a high demand for energy [2] and metabolites [3]. The shape of mitochondria is also directly regulated by mitochondrial intermembrane proteins and their accessory proteins [4]. Numerous researchers have studied the role of these proteins in various cell types in determining the shape of mitochondria. However, the results of these studies are rather uninformative and lack an understanding of the underlying mechanisms, especially in stem cells. In this review, we describe the basic mechanisms of the proteins involved in mitochondrial dynamics. Furthermore, we focus on how these proteins affect the cellular metabolism, reprogramming, differentiation, and aging.

## 2. Components determining the mitochondrial structure

Mitochondria are present in most cell types and tissues, and mitochondrial shape is changed exquisitely by the process of fusion and fission. Mitochondrial movement and nuclear fission were observed under an optical microscope nearly 100 years ago [5]. This process is involved in the growth and division of mitochondria and is important in maintaining the number and functions of mitochondria [6].

Mitochondrial fission is regulated by post-translational modification of the Drp1 protein, including modification by phosphorylation, S-nitrosylation, small ubiquitin-like modifier (SUMO)-ylation, ubiquitination, and O-GlcNAc modification (O-GlcNAcylation) in response to a variety of cellular stimuli [12]. Mitochondrial fusion is a two-step process involving the mitochondrial outer membrane (MOM) fusion, mediated by mitofusin proteins (Mfn1 and Mfn2) [13-17] and mitochondrial inner membrane (MIM) fusion, mediated by Opa1, and could be possibly coupled [18-20]. We describe here the functions of proteins involved in mitochondrial fusion and fission (Fig. 1).



**Figure 1.** Schematic illustration of the mitochondrial dynamics. Mitochondria dynamically change their morphology through the cycle of fusion and fission. Main fusion factors are OPA1 and MFN1 and MFN2, which bind to the inner membrane (MIM) and outer membrane (MOM) of mitochondria. Drp1 is major fission factor that bind to MOM and form ring-like structure around mitochondria leading to the separation of mitochondria into two. Mff, Fis1, Mid49, and Mid51 function as adaptors to recruit Drp1 to the MOM.

**2.1. Mitochondrial fission proteins**

Mitochondrial division in a cell contributes to ensuring proper distribution and quality control of mitochondria, which maintain a cell in a healthy state. A member of the dynamin family of GTPases, dynamin-like 1 (Dnm1), which is also referred to as dynamin related protein 1 (Drp1), is a major player of mitochondrial division [21-23]. Genetic and biochemical studies in yeast have shown that Dnm1-mediated mitochondrial cleavage requires the tail-anchored MOM protein Fis1 and its two adaptor protein Mdv1 or its paralogue Caf4, which connect Dnm1 to Fis1 [6, 24-31]. During mitochondrial division, Fis1 transiently interacts with cytosolic Dnm1 by the tetratricopeptide-repeat motif via the cytosolic adapter protein Mdv1/Caf4, indicating that Fis1 functions as a mitochondrial Dnm1 receptor [27]. However, Mdv1 and its homologs (Caf4, Num1, and Mdm36) were not found in mammalian cells, indicating that only two proteins, Dnm1 and Fis1, are conserved in all species that contain mitochondria [32]. Several fission-related proteins have been identified in mammals, but the detailed mechanistic role in mitochondrial fission has not been clarified.

## 2.2. Mitochondrial fission accessory proteins

Besides the major mitochondrial fission proteins, mitochondrial fission accessory proteins such as mitochondrial fission factor (Mff), mitochondrial dynamics 49 (MiD49), mitochondrial dynamics 51 (MiD51), ganglioside-induced differentiation-associated protein 1 (GDAP1), and endophilins additionally play crucial roles in mitochondrial fission.

Mff is a C-terminal-tail immobilized protein recently identified in a *Drosophila* RNA interference (RNAi) library used to search for mitochondrial morphological changes. Mammalian mitochondria also contain an orthologue of Mff, suggesting that Mff may be involved in the mitochondrial division and fission in mammalian cells [33]. Mff overexpression caused mitochondrial fragmentation, similar to Drp1 overexpression in mammalian cells [33–35]. Consistent with these observations, *in vitro* and *in vivo* experiments have demonstrated that Mff transiently interacts with Drp1 through the N-terminal cytoplasmic domain.

MiD51 and MiD49 variants, known as mitochondrial elongation factor 1 and 2 (MIEF1/2), respectively, are MOM proteins identified by random cell localization screens of raw proteins that cause unique distribution and changes in mitochondrial morphology [36]. MIEF1/2 form foci and rings around mitochondria and directly recruit cytosolic Drp1 to the mitochondrial outer membrane surface [37], serving as adaptors linking Drp1 and Mff [36]. Therefore, MIEF1/2 was suggested to be a receptor for Drp1 and mediator of mitochondrial division (fission). MIEF1/2 knockdown by RNAi resulted in the reduction of interaction of Drp1 with mitochondria, leading to mitochondrial elongation. Surprisingly, overexpression of MIEF1/2 induced mitochondrial fission by sequestering Drp1 protein activity [36, 37]. Zhao *et al.*, on the other hand, claimed that the knockdown of MIEF1 by RNAi induces mitochondrial fragmentation. They concluded that MIEF1 functions as a Drp1 suppressor that inhibits GTPase-dependent fission activity of Drp1 and MIEF1 also has a role independent of Mfn2 in the fusion pathway [38]. Given the discrepancy, more research concerning MIEF1/2 has to be carried out.

GDAP1 is another mitochondrial division-related factor located on the MOM through the C-terminal hydrophobic transmembrane domain, which pushes the bulk N-terminal domain to the cytoplasm [39]. It is expressed in myelinating Schwann cells and motor and sensory neurons [40]. The GDAP1 mutation induced progression to peripheral nerve injury Charcot-Marie-Tooth disease, with primary axonal damage and primary dehydration of the peripheral nerve [41]. GDAP1 mutants found in patients with the Charcot-Marie-Tooth disease do not target mitochondria and lack mitochondrial cleavage activity [42]. GDAP1-induced mitochondrial fragmentation is inhibited by Drp1 knockdown or the expression of a dominant-negative Drp1-K38A mutation, indicating that GDAP1 is a Drp1-dependent modulator of mitochondrial division [43].

Endophilins, fatty acyl transferases, were proposed to mediate membrane curvature changes and participate in membrane cleavage during endocytosis and intracellular organelle biogenesis [44]. They have an N-terminal Bar domain interacting with the membrane and a C-terminal SH3 domain mediating protein binding [45–48]. Endophilin B1 (also called Endo B1, Bif-1) was identified by a yeast two-hybrid protein screen to bind to Bax, a proapoptotic Bcl-2 family member, and was reported to be involved in apoptosis, mitochondrial morphogenesis, and autophagosome formation [49–52].

## 2.3. Mitochondrial fusion proteins

At the molecular level, mitochondrial fusion is a two-step process that requires coordinated sequential fusion of the MOM and MIM [53–55]. In mammals, this process relies on the unique mitochondrial sub-localization of the three fusion-related proteins: the MOM-located mitofusin 1 and 2 (Mfn1 and Mfn2) and MIM-located optic atrophy 1 (Opa1) [16, 56].

The mitofusin proteins Mfn1 and Mfn2 belong to the ubiquitous transmembrane GTPase family, which is conserved from yeast to humans [57, 58]. Mfn1 and Mfn2 share about 80% similarity and show the same structural motifs [15]. Their amino terminal GTPase domain contains five motifs, each of which plays an important role in GTP binding and hydrolysis [59]. Notably, the proline-rich region (PR) involved in protein-protein interactions is found only in Mfn2. Mfn1 and Mfn2 double-knockout (DKO) mice die prematurely during pregnancy due to insufficient mitochondrial fusion in the placenta [17, 60]. Interestingly, double-mutant embryos die without any visible developmental defect, suggesting the non-redundant function of Mfn1 and Mfn2 in embryonic development. Indeed, Mfn1 mediates mitochondrial docking and fusion more efficiently than Mfn2, presumably due to its high GTPase activity [61]. Furthermore, Mfn1 is required to mediate Opa1-induced mitochondrial fusion, but not Mfn2 [19].

Opa1 is also a dynamin family GTPase that promotes IMM fusion following OMM fusion [18, 62]. Cryo-immunogold EM analysis revealed that Opa1 is a mitochondrial intermembrane space protein [63]. Opa1 function is controlled in part by proteolysis, by which Opa1 is cleaved and mitochondrial fusion is blocked [64, 65]. Proteolytic inactivation of Opa1 could induce the change of mitochondrial morphology, such as swelling and constriction of mitochondrial tubules and swollen cristae [63]. In addition, Opa1 was suggested to help maintain cristae morphology like Mitofilin and ATP synthase [66]. As cristae shape is important for the assembly of respiratory chain complexes and respiratory efficiency, Opa1 may be essential for the proper assembly and function of the electron transport supercomplex [20, 67].

#### 2.4. Mitochondrial fusion accessory proteins

Besides the three major mitochondrial fusion proteins, some accessory proteins, such as PINK1 (protein phosphatase and tensin homolog (PTEN)-induced kinase 1) and PARKIN, could affect the mitochondrial fusion machinery. PINK1 is a ubiquitin kinase that phosphorylates ubiquitin and subsequently activate the ubiquitin ligase PARKIN. PINK1 and PARKIN have been suggested as inducing factors for mitophagy. When PINK1 is stabilized on the MOM of malfunctioning mitochondria, PINK1 recruits ubiquitin E3 ligase kinase and autophagy receptors, which leads to autophagosome biogenesis and subsequent catabolism by lysosomes [68]. PINK1 protein or PINK1 kinase has little activity in normal mitochondria [69]. However, when depolarization occurs in the mitochondria, the PINK1 process is stopped and PINK1 accumulates and phosphorylates the substrate proteins [70]. Healthy mitochondria actively degrade PINK1 to prevent mitophagic destruction. However, damaged mitochondria could no longer trigger PINK1 degradation, and resulted in the accumulation of PINK1 in mitochondria followed by the mitotic destruction of the organelle [71].

Parkinson's disease can be caused by a mutation in Pink1 or Parkin, which may lead to the accumulation of damaged mitochondria in neurons. Ultimately, damaged mitochondria in patients with Parkinson's disease can kill cells through ROS or other toxic substances in dopaminergic neurons [72].

PARKIN (also known as PARK2) is an E3 ubiquitin ligase recruited to MOM by PINK1 [73]. PARKIN ubiquitinates several mitochondrial proteins to stimulate mitophagy [74]. The PARKIN-mediated mitophagy is also linked to mitochondrial fission because mitochondrial fragmentation is essential for engulfment of mitochondria by autophagosomes [75]. PINK-PARKIN pathway plays an important role in mitochondrial fusion [76, 77] though detailed mechanism remains poorly understood. Mitochondria can structurally and functionally contact with other intracellular organelles. Endoplasmic reticulum (ER) and mitochondria can communicate with each other through mitochondria-associated membranes (MAMs). The MAM is an important regulator of mitochondrial and cell functions, such as mitochondrial division, apoptosis, lipid and  $\text{Ca}^{2+}$  biogenesis [78].

3. Cellular metabolism and mitochondrial dynamics

The well-known function of mitochondria is the production of energy in the form of ATP via oxidative phosphorylation (OXPHOS), which occurs in the mitochondrial cristae [79]. Besides, the diverse functions of mitochondria are intimately related with their morphology. However, the relationships between mitochondrial dynamics and cellular metabolism are generally veiled because of the complex mechanisms involved, involvement of multiple factors across the cellular environment, cell type variation, and differences between metabolic cues [80]. This is evident from the challenges faced by many researchers in identifying the machinery of mitochondrial dynamics and metabolism in different cell types; many pioneering studies on mitochondrial dynamics from yeast have tried to address these challenges.

3.1. The mitochondrial morphologies and energy metabolism in various stem cells

Well-developed mitochondria are generally thought to produce energy, or ATP, more efficiently than the immature, globular mitochondria. Since well-developed mitochondria have complex cristae structures, they have a greater surface area to accommodate a larger number of inter-membrane proteins for energy production [81]. In fact, some reports showed that fused and interconnected mitochondrial structures are found in cells that depend mainly on OXPHOS for energy production [82]. However, the cells which have non-fused spherical (immature form) mitochondria have a tendency to produce energy mainly via glycolytic metabolism [83]. Therefore, cell types containing poorly developed mitochondria mainly have OXPHOS-independent metabolism. However, there are some exceptions to this, as seen in various stem cell types (Table. 1). Actively proliferating cells, such as stem cells and cancer cells, use aerobic glycolysis for energy production.

Table 1. Mitochondrial morphology and energy metabolism in various cell types

Cell type	Potency	Morphology	Predominant Energy metabolism	Reference
Embryonic stem cells (ESCs)	Naïve pluripotency	Non-fused spherical	Glycolysis (Higher OXPHOS than EpiSCs)	[84]
Epiblast stem cells (EpiSCs)	Primed pluripotency	Non-fused spherical	Glycolysis	[84]
Neural stem cells (NSCs)	Multipotency	Fused elongated	Glycolysis	[85, 86]
Neural progenitor cells (NPCs)	Multipotency	Non-fused spherical	Glycolysis	[85, 86]
Neurons	-	Fused elongated	OXPHOS	[85, 86]
Mesenchymal stem cells (MSCs)	Multipotency	Fused elongated	Glycolysis	[87]
Hematopoietic stem cells (HSCs)	Multipotency	Fused elongated	Glycolysis	[88]
Hematopoietic progenitor cells (HPCs)	Multipotency	Fused elongated	Glycolysis (Higher OXPHOS than HSCs)	[89]



There are two types of pluripotent stem cells (PSCs), naïve and primed PSCs. Naïve PSCs, such as mouse embryonic stem cells (mESCs), are the in vitro counterparts of inner cell mass (ICM) of preimplantation blastocyst and primed PSCs, such as mouse epiblast stem cells (mEpiSCs), are the in vitro counterparts of epiblast of postimplantation embryos. The morphology of mEpiSCs is more tubular and fused shape compared to naïve pluripotent state mESCs, but mESCs showed higher OXPHOS activity than mEpiSCs [84].

Moreover, embryonic mouse NSCs have been found to depend on aerobic glycolytic metabolism though they have a relatively fused mitochondrial network [86, 90]. On the other hand, neurons terminally differentiated from NSCs rely on OXPHOS for energy metabolism, even if they have a fused mitochondrial network similar to NSCs. Meanwhile, mouse NPCs whose differentiation state is in between NSCs and neurons, had more fragmented mitochondria compared with NSCs and neurons; however, they utilized aerobic glycolysis for major energy metabolism [86]. Metabolic shift from glycolysis to OXPHOS during the differentiation of NSCs occurred around the time of transition from NSCs to intermediate progenitor cells [85].

MSCs, which have multipotent differentiation potential to all blood cell types, have glycolysis-dependent energy metabolism [87]. They showed the relatively more tubular shape of mitochondria that can further elongate upon differentiation, as observed in NSC differentiation [91].

HSCs mainly use glycolysis for energy metabolism [88]. However, further differentiated HPCs were suggested to be more OXPHOS-dependent than HSCs [89]. This phenomenon might be a response of HSCs in the hypoxic environment of bone marrow to limit the production of ROS from the respiratory chain complexes in mitochondria [92]. Recently, Luchsinger *et al.* showed that the differentiation of HSCs was accompanied by mitochondrial OXPHOS activation. HSCs express more Mfn2 than differentiated hematopoietic lineages, indicating that they contain elongated mitochondria as Mfn2 expression level is correlated with mitochondrial length [93].

### 3.2. Warburg effect: survival strategy of proliferative glycolytic cells

As described above, most adult stem cells mainly used aerobic glycolysis for ATP production. This kind of phenomenon found in stem cells is known as “Warburg effect” which was first described in cancer cells [94]. Most cancer cells produce energy through a high rate of glycolysis even when there is sufficient oxygen supply, a phenomenon termed the “Warburg effect”. The precise mechanism of the Warburg effect remains unknown. This phenomenon was paid attention in the process of cellular reprogramming, or induced pluripotent stem cell (iPSC) generation [95] and metabolic switch from OXPHOS in mouse embryonic fibroblasts (MEFs) to glycolysis in reprogrammed iPSCs. This phenomenon is commonly observed in various kinds of cancers which display a highly proliferative state. Then, this raises the question of why proliferating cells choose an inefficient pathway to produce energy? Cell division requires not only energy but also various kinds of cellular constituents, such as nucleotides, amino acids, and lipids. Glycolysis along with pentose phosphate pathway can account for cellular constituents as well as ATP [96]. Reduction in mitochondrial metabolism may also allow in maintaining a low level of harmful free radicals such as ROS. Therefore, glycolysis would be beneficial to the actively proliferating stem cells to self-renew and maintain cell states [97].


### 3.3. Metabolic regulation in mitochondria for the maintenance of pluripotent state

In addition to the energy metabolism, mitochondria also play a crucial role in the stemness of PSCs. For example, PSCs showed a high level of uncoupling protein 2 (UCP2) protein [98], which is located in the membrane between inter-membrane space and matrix, and functioned as metabolites transportation to the out of the mitochondria, thereby regulating glucose and glutamine oxidation [99]. Mitochondrial metabolism is also important for the self-renewal capacity of human PSCs.

Zhang *et al.* reported that although glycolysis supported stemness of human PSCs under all conditions, oxidative mitochondrial metabolism was also highly active in human PSCs when they were cultured in a media containing lipid supplements [100]. This may highlight the importance of cellular environment or culture condition, which could affect mitochondrial function and related mitochondrial morphology in human PSCs.

**4. Mitochondrial dynamics in the reprogramming process**

The proteins related to mitochondrial dynamics, such as fusion and fission, are interestingly crucial for pluripotential reprogramming. During reprogramming (iPSC generation) and re-differentiation of iPSCs, mitochondrial morphology dynamically changed (Fig. 2); mitochondria became elongated during reprogramming and became globular-shaped after re-differentiation into a neural lineage [101]. As the mitochondrial morphology changes dynamically during the process of reprogramming, the metabolic profile switches from OXPHOS to glycolysis [101-104]. Several studies suggested that the mitochondrial dynamics and energy metabolism are critical for the reprogramming process.



**Figure 2.** Dynamic change of mitochondrial shape during the reprogramming and differentiation. Elongated mitochondria in differentiated cells become spherical shape during the formation of iPS cells. As iPS cells differentiate, mitochondria resort back to the elongated shape.

**4.1. Mitochondrial fission proteins affect pluripotential reprogramming**

Here we will discuss how the mitochondrial fission proteins affect the reprogramming process. Mdivi-1 treatment, which inhibits mitochondrial fission protein DRP1, was sufficient to suppress the early stage of reprogramming of somatic cells [105]. Moreover, iPSCs lost pluripotency when exposed to Mdivi-1, indicating that mitochondrial fission is important for gaining and maintaining pluripotency.

Reduced expression 1 (REX1), which function in the maintenance of pluripotency, induces phosphorylation of DRP1 at Ser616 and mitochondrial fission [106]. On the other hand, the inhibition of the oncogenic mitogen-activated protein kinase (MAPK) cascade leads to robust mitochondrial fusion via the loss of phosphorylation in DRP1 serine 616 through ERK1/2 protein [107]. Therefore, Drp1 phosphorylation by ERK pathway is necessary for the pluripotential reprogramming process [108]. Furthermore, inhibition of the accessory proteins, such as Gdap1, Mid51, and Mff, which control Drp1 recruitment to the mitochondria, suppressed reprogramming due to impaired mitochondrial fission. In particular, Gdap1-null cells displayed G2/M growth arrest in cells undergoing reprogramming and affected the early phase in reprogramming [109]. Collectively, change in mitochondrial dynamics and cell cycle are crucial factors for efficient reprogramming of cells.

#### 4.2. Mitochondrial fusion proteins affect pluripotential reprogramming

Mitochondrial fusion proteins can also affect reprogramming efficiency through a different pathway from that of fission proteins. Son *et al.* revealed that depletion of mitochondrial fusion proteins, such as Mfn1 and Mfn2, increased efficiency of somatic cell reprogramming into iPSCs as well as maintained pluripotency [110]. They also showed that Mfn1 and Mfn2 depletion facilitates the transition of OXPHOS to glycolytic metabolism, because Mfn1 and Mfn2 are inhibitors of reprogramming as they directly bind to Ras and Raf and thus inhibit cell proliferation. Inhibition of Mfn1 and Mfn2 also activated ROS-mediated hypoxia-inducible factor 1 $\alpha$  (HIF1 $\alpha$ ) signaling at an early stage and established the reprogramming favorable hypoxic condition [110].

### 5. Mitochondrial dynamics in the differentiation process

During the process of PSC differentiation, changes in mitochondrial morphology and metabolite composition are essential among the various differentiated cell types [111]. As PSCs mainly use glycolysis, and differentiated cells use OXPHOS for ATP production, respectively, inhibition of mitochondrial OXPHOS during the differentiation of PSCs leads to defect in differentiation and instead, supports the maintenance of pluripotency. In line with this, the proteins related to mitochondrial dynamics also play a crucial role in the differentiation process.

#### 5.1. Mitochondrial fission proteins affect cellular differentiation

Several reports showed that Drp1-dependent mitochondrial fission is crucial for embryonic and cellular differentiation *in vivo* and *in vitro*. Drp1-null mice showed defective trophoblast giant cells and decreased cardiomyocyte beat rates and died around 11.5 dpc; however they showed normal levels of intracellular ATP [112, 113]. Conditional knockout of Drp1 showed defect in cerebella during postnatal development. Neural cell-specific Drp1 knockout mice displayed brain hypoplasia and *in vitro* culture of the forebrain showed a reduction in the number of neurites and abnormal synapse formation [112, 113]. However, heterozygote knockout of Drp1 did not affect mitochondrial and synaptic viability [114]. Kim *et al.* showed that inhibiting Drp1 activity induced morphological change of migratory adult NSCs, which causes abnormal migration and prevention of neuronal differentiation in the NSCs [115].

During cellular maturation, mitochondrial localization and distribution is under the control of cellular states, such as cell division, migration etc. Therefore, the localization of mitochondria is dynamically regulated during neuronal maturation and myogenic differentiation [116]. During neuronal differentiation, mitochondria accumulate in the regions where high energy is required such as growth cones at the early stage of differentiation and then localize at presynaptic terminals following neuron maturation [115]. In myogenic differentiation, NO/cGMP control Drp1 localization and activity and stimulate myogenesis through inhibition of Drp1-dependent mitochondrial fission [116]. Furthermore, Mdivi-1 mediated Drp1 inhibition suppressed expression levels of key myogenic regulatory factors (MRFs) such as MyoD and Myogenin in differentiating C2C12 cells, a mouse muscle myoblast [117]. Likewise, myogenic differentiation of C2C12 myoblasts required Drp1-mediated mitophagy [118]. Recent report also suggested that knock-down or inhibition of Drp1 by using Mdivi-1 promotes differentiation into cardiac mesoderm lineage from human PSCs [119].

Fis1 function in stem cells and differentiation has only been reported recently. Pei *et al.* showed that gene expression level of Fis1 was specifically high in leukemia stem cells and it functions as a crucial mitochondrial morphology regulator [120]. They also showed that loss of Fis1 impairs mitochondrial dynamics and induces myeloid differentiation in acute myeloid leukemia.



## 5.2. Mitochondrial fusion proteins affect cellular differentiation

Besides mitochondrial fission, mitochondrial fusion additionally executes crucial roles in cellular differentiation process, especially in cardiac, neural, and mesenchymal differentiation. The deletion of *Mfn1* and *Mfn2* in the mouse embryonic hearts impaired mouse heart development, and ablation of *Mfn2* or *Opa1* in mouse ESCs resulted in defective cardiac differentiation of the ESCs [121]. Gene expression profiling showed that mitochondrial morphology-related genes interacted with calcineurin to regulate Notch1 signaling that control cardiac differentiation [121]. Similarly, proteins that drive mitochondrial fusion, such as MFN (mitofusin) 1 and 2 and OPA1, are required for the differentiation of stem cells into cells that depend on OXPHOS metabolism, like cardiomyocytes and neurons [121, 122].

Mitochondrial dynamics is also involved in MSC differentiation, including adipogenesis, osteogenesis, and chondrogenesis. Mitochondrial elongation (increase in *Mfn1* and *Mfn2* expression) is correlated with the adipogenesis and osteogenesis, and mitochondrial fragmentation (increased expression of *Drp1*, *Fis1*, and *Fis2*) is involved in chondrogenesis. Consequently, knockdown of *Mfn2* and the overexpression of a dominant negative form of *Drp1* resulted in defective differentiation in adipo- and osteogenesis, and chondrogenesis, respectively [91].

During the differentiation of human iPSCs into neurons, expression level of *Mfn2* increased with time after differentiation [122]. Knockdown of *Mfn2* results in mitochondrial dysfunctions, such as downregulated expression of complexes I and IV, and ATP levels, and impaired neuronal differentiation. On the contrary, *Mfn2* overexpression in NPCs promotes neuronal differentiation with enhanced mitochondrial bioenergetics and functions. Taken together, many studies have shown that mitochondrial fusion and fission play crucial roles in various cellular differentiation processes through the control of bioenergetics, signaling pathways, or expression of tissue-specific genes.

## 6. The Mitochondrial dynamics in aging

Mitochondria also play an important role in cellular aging and cell death associated with necrosis, apoptosis, autophagy, and mitophagy through the modulation of redox by reduction reaction mechanisms [123, 124]. The process of aging may be associated with the accumulation of damages, such as production of metabolic by-products and ROS, accumulation of biological waste products, telomere shortening, and dysregulation of metabolic pathways [125-127]. Most of these aging factors are associated with mitochondrial dynamics and functions, indicating the close relationship between aging and mitochondria.

### 6.1. Mitochondrial ROS impact on cellular senescence-related mitochondrial dynamics

Abnormally elongated mitochondria are often observed in various senescent cells, implying that mitochondrial dynamics may have a functional role in cell senescence and aging. This phenomenon could be caused by the alteration of expression patterns of genes associated with mitochondrial fission, such as *Drp1* and *Fis1*, and with mitochondrial fusion, such as *Mfn1* and *Mfn2*. Mai *et al.* reported that the senescent human endothelial cells (HUVECs) showed reduced expression levels of *DRP1* and *FIS1* that caused long interconnected mitochondria [128]. The loss of *DRP1* exacerbated endothelial cell dysfunction by inhibiting autophagic flux accompanied by increasing mitochondrial ROS [129]. In addition, the regulation of ROS by mitochondrial fission is dependent on protein disulfide isomerase A1 (PDIA1) in mouse endothelial cells; PDIA1-depleted endothelial cells activated mitochondrial fission [130]. Recently, Leduc-Gaudet *et al.* also suggested that the levels of mitochondrial dynamics-related proteins, including *Mfn1*, *Mfn2*, *Opa1*, and *Drp1*, were not significantly different between young and aged skeletal muscles [131]. However, the ratio between *Mfn2* and *Drp1* protein expression levels could define the extent of aging in skeletal muscle

cells; as skeletal muscle cells grew older, the ratio of Mfn2/Drp1 significantly increased [131]. On the other hand, Debastian et al. suggested that the expression level of Mfn2 in skeletal muscle decreased during aging [132]. Mfn2 deficiency in skeletal muscle caused the reduction of mitochondrial respiration and elevation of oxidative stress, which was accompanied by the activation of the transcription factor, HIF1 $\alpha$ , to minimize the accumulation of damaged mitochondria [132]. Thus, Mfn2 functions as a regulator in mitophagy and consequently controls the mitochondrial quality control pathway. Moreover, the stress-responsive mitochondrial protein, Sirt4 was suggested to have implications in aging. Similar to Mfn2-functioning in mitophagy, Sirt4 could promote mitochondrial fusion by interacting with Opa1 and reduce mitophagy [133]. Overall, various aging factors are interconnected, and of these, mitochondrial dysfunction and dynamics are the underlying mechanism of cellular aging.

7. Conclusions

In this review, we have discussed the widespread involvement of mitochondria in various cellular processes such as cell survival, cell cycle, proliferation, differentiation, reprogramming, aging, and energy metabolism. The variety of functions carried out by mitochondria implicates that the normal mitochondrial dynamics controlled by mitochondrial fusion/fission are critical for human health. Clinically, defect in mitochondrial fusion/fission causes diseases including optic atrophy, Charcot-Marie-Tooth disease, Parkinson's disease, and Alzheimer's disease [134-139]. Thus, further understanding of mitochondrial dynamics is of paramount importance in elucidating mechanisms of diseases at the cellular level and discovering novel therapies to cure associated diseases.

**Author Contributions:** B.J.S., S.H.Y., and J.T.D. wrote the paper.

**Funding:** This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning of the Republic of Korea (grant nos. 2016M3A9B6946835 and 2015R15A1009701). This paper was written as part of Konkuk University's research support program for its faculty on sabbatical leave in 2018.

**Conflicts of Interest:** The authors declare no conflict of interest.

Abbreviations

MOM	Mitochondrial outer membrane
MIM	Mitochondrial inner membrane
MAM	Mitochondria-associated membrane
OXPHOS	Oxidative phosphorylation
ESC	Embryonic stem cell
EpiSC	Epiblast stem cell
NSC	Neural stem cell
NPC	Neural progenitor cell
MSC	Mesenchymal stem cell
HSC	Hematopoietic stem cell
HPC	Hematopoietic progenitor cell
PSC	Pluripotent stem cell
iPSC	Induced pluripotent stem cell
MEF	Mouse embryonic fibroblast
HUVEC	Human endothelial cell

References

1. Dunwoodie, S. L., The role of hypoxia in development of the Mammalian embryo. *Developmental cell* **2009**, 17, (6), 755-73.

2. Morrow, R. M.; Picard, M.; Derbeneva, O.; Leipzig, J.; McManus, M. J.; Gouspillou, G.; Barbat-Artigas, S.; Dos Santos, C.; Hepple, R. T.; Murdock, D. G.; Wallace, D. C., Mitochondrial energy deficiency leads to hyperproliferation of skeletal muscle mitochondria and enhanced insulin sensitivity. *Proceedings of the National Academy of Sciences of the United States of America* **2017**, *114*, (10), 2705-2710.
3. Frezza, C., Mitochondrial metabolites: undercover signalling molecules. *Interface focus* **2017**, *7*, (2), 20160100.
4. Chen, H.; Chan, D. C., Mitochondrial dynamics--fusion, fission, movement, and mitophagy--in neurodegenerative diseases. *Human molecular genetics* **2009**, *18*, (R2), R169-76.
5. Lewis, M. R.; Lewis, W. H., Mitochondria (and other cytoplasmic structures) in tissue cultures. *Amer. J Anat.* **1915**, *17*, (3).
6. Okamoto, K.; Shaw, J. M., Mitochondrial morphology and dynamics in yeast and multicellular eukaryotes. *Annual review of genetics* **2005**, *39*, 503-36.
7. Rizzuto, R.; Brini, M.; Murgia, M.; Pozzan, T., Microdomains with high Ca<sup>2+</sup> close to IP<sub>3</sub>-sensitive channels that are sensed by neighboring mitochondria. *Science* **1993**, *262*, (5134), 744-7.
8. Dimmer, K. S.; Scorrano, L., (De)constructing mitochondria: what for? *Physiology* **2006**, *21*, 233-41.
9. de Brito, O. M.; Scorrano, L., An intimate liaison: spatial organization of the endoplasmic reticulum-mitochondria relationship. *The EMBO journal* **2010**, *29*, (16), 2715-23.
10. Zuchner, S.; Mersyanova, I. V.; Muglia, M.; Bissar-Tadmouri, N.; Rochelle, J.; Dadali, E. L.; Zappia, M.; Nelis, E.; Patitucci, A.; Senderek, J.; Parman, Y.; Evgrafov, O.; Jonghe, P. D.; Takahashi, Y.; Tsuji, S.; Pericak-Vance, M. A.; Quattrone, A.; Battaloglu, E.; Polyakov, A. V.; Timmerman, V.; Schroder, J. M.; Vance, J. M., Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. *Nature genetics* **2004**, *36*, (5), 449-51.
11. Misko, A. L.; Sasaki, Y.; Tuck, E.; Milbrandt, J.; Baloh, R. H., Mitofusin2 mutations disrupt axonal mitochondrial positioning and promote axon degeneration. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **2012**, *32*, (12), 4145-55.
12. Chang, C. R.; Blackstone, C., Dynamic regulation of mitochondrial fission through modification of the dynamin-related protein Drp1. *Annals of the New York Academy of Sciences* **2010**, *1201*, 34-9.
13. Santel, A.; Fuller, M. T., Control of mitochondrial morphology by a human mitofusin. *Journal of cell science* **2001**, *114*, (Pt 5), 867-74.
14. Legros, F.; Lombes, A.; Frachon, P.; Rojo, M., Mitochondrial fusion in human cells is efficient, requires the inner membrane potential, and is mediated by mitofusins. *Molecular biology of the cell* **2002**, *13*, (12), 4343-54.
15. Santel, A.; Frank, S.; Gaume, B.; Herrler, M.; Youle, R. J.; Fuller, M. T., Mitofusin-1 protein is a generally expressed mediator of mitochondrial fusion in mammalian cells. *Journal of cell science* **2003**, *116*, (Pt 13), 2763-74.
16. Eura, Y.; Ishihara, N.; Yokota, S.; Mihara, K., Two mitofusin proteins, mammalian homologues of FZO, with distinct functions are both required for mitochondrial fusion. *Journal of biochemistry* **2003**, *134*, (3), 333-44.
17. Chen, H.; Detmer, S. A.; Ewald, A. J.; Griffin, E. E.; Fraser, S. E.; Chan, D. C., Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. *The Journal of cell biology* **2003**, *160*, (2), 189-200.
18. Olichon, A.; Baricault, L.; Gas, N.; Guillou, E.; Valette, A.; Belenguer, P.; Lenaers, G., Loss of OPA1 perturbs the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. *The Journal of biological chemistry* **2003**, *278*, (10), 7743-6.
19. Cipolat, S.; Martins de Brito, O.; Dal Zilio, B.; Scorrano, L., OPA1 requires mitofusin 1 to promote mitochondrial fusion. *Proceedings of the National Academy of Sciences of the United States of America* **2004**, *101*, (45), 15927-32.
20. Frezza, C.; Cipolat, S.; Martins de Brito, O.; Micaroni, M.; Beznoussenko, G. V.; Rudka, T.; Bartoli, D.; Polishuck, R. S.; Danial, N. N.; De Strooper, B.; Scorrano, L., OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. *Cell* **2006**, *126*, (1), 177-89.
21. Smirnova, E.; Shurland, D. L.; Ryazantsev, S. N.; van der Bliek, A. M., A human dynamin-related protein controls the distribution of mitochondria. *The Journal of cell biology* **1998**, *143*, (2), 351-8.
22. Smirnova, E.; Griparic, L.; Shurland, D. L.; van der Bliek, A. M., Dynamin-related protein Drp1 is required for mitochondrial division in mammalian cells. *Molecular biology of the cell* **2001**, *12*, (8), 2245-56.
23. Ingeman, E.; Perkins, E. M.; Marino, M.; Mears, J. A.; McCaffery, J. M.; Hinshaw, J. E.; Nunnari, J., Dnm1 forms spirals that are structurally tailored to fit mitochondria. *The Journal of cell biology* **2005**, *170*, (7), 1021-7.

24. Hoppins, S.; Lackner, L.; Nunnari, J., The machines that divide and fuse mitochondria. *Annual review of biochemistry* **2007**, 76, 751-80.
25. Mozdy, A. D.; McCaffery, J. M.; Shaw, J. M., Dnm1p GTPase-mediated mitochondrial fission is a multi-step process requiring the novel integral membrane component Fis1p. *The Journal of cell biology* **2000**, 151, (2), 367-80.
26. Otsuga, D.; Keegan, B. R.; Brisch, E.; Thatcher, J. W.; Hermann, G. J.; Bleazard, W.; Shaw, J. M., The dynamin-related GTPase, Dnm1p, controls mitochondrial morphology in yeast. *The Journal of cell biology* **1998**, 143, (2), 333-49.
27. Naylor, K.; Ingeman, E.; Okreglak, V.; Marino, M.; Hinshaw, J. E.; Nunnari, J., Mdv1 interacts with assembled dnm1 to promote mitochondrial division. *The Journal of biological chemistry* **2006**, 281, (4), 2177-83.
28. Karren, M. A.; Coonrod, E. M.; Anderson, T. K.; Shaw, J. M., The role of Fis1p-Mdv1p interactions in mitochondrial fission complex assembly. *The Journal of cell biology* **2005**, 171, (2), 291-301.
29. Tieu, Q.; Nunnari, J., Mdv1p is a WD repeat protein that interacts with the dynamin-related GTPase, Dnm1p, to trigger mitochondrial division. *The Journal of cell biology* **2000**, 151, (2), 353-66.
30. Lackner, L. L.; Nunnari, J. M., The molecular mechanism and cellular functions of mitochondrial division. *Biochimica et biophysica acta* **2009**, 1792, (12), 1138-44.
31. Lackner, L. L.; Horner, J. S.; Nunnari, J., Mechanistic analysis of a dynamin effector. *Science* **2009**, 325, (5942), 874-7.
32. Otera, H.; Ishihara, N.; Mihara, K., New insights into the function and regulation of mitochondrial fission. *Biochimica et biophysica acta* **2013**, 1833, (5), 1256-68.
33. Otera, H.; Wang, C.; Cleland, M. M.; Setoguchi, K.; Yokota, S.; Youle, R. J.; Mihara, K., Mff is an essential factor for mitochondrial recruitment of Drp1 during mitochondrial fission in mammalian cells. *The Journal of cell biology* **2010**, 191, (6), 1141-58.
34. Otera, H.; Mihara, K., Molecular mechanisms and physiologic functions of mitochondrial dynamics. *Journal of biochemistry* **2011**, 149, (3), 241-51.
35. Otera, H.; Mihara, K., Discovery of the membrane receptor for mitochondrial fission GTPase Drp1. *Small GTPases* **2011**, 2, (3), 167-172.
36. Yu, R.; Liu, T.; Jin, S. B.; Ning, C.; Lendahl, U.; Nister, M.; Zhao, J., MIEF1/2 function as adaptors to recruit Drp1 to mitochondria and regulate the association of Drp1 with Mff. *Scientific reports* **2017**, 7, (1), 880.
37. Palmer, C. S.; Osellame, L. D.; Laine, D.; Koutsopoulos, O. S.; Frazier, A. E.; Ryan, M. T., MiD49 and MiD51, new components of the mitochondrial fission machinery. *EMBO reports* **2011**, 12, (6), 565-73.
38. Zhao, J.; Liu, T.; Jin, S.; Wang, X.; Qu, M.; Uhlen, P.; Tomilin, N.; Shupliakov, O.; Lendahl, U.; Nister, M., Human MIEF1 recruits Drp1 to mitochondrial outer membranes and promotes mitochondrial fusion rather than fission. *The EMBO journal* **2011**, 30, (14), 2762-78.
39. Wagner, K. M.; Ruegg, M.; Niemann, A.; Suter, U., Targeting and function of the mitochondrial fission factor GDAP1 are dependent on its tail-anchor. *PloS one* **2009**, 4, (4), e5160.
40. Pedrola, L.; Espert, A.; Valdes-Sanchez, T.; Sanchez-Piris, M.; Sirkowski, E. E.; Scherer, S. S.; Farinas, I.; Palau, F., Cell expression of GDAP1 in the nervous system and pathogenesis of Charcot-Marie-Tooth type 4A disease. *Journal of cellular and molecular medicine* **2008**, 12, (2), 679-89.
41. Cassereau, J.; Chevrollier, A.; Bonneau, D.; Verny, C.; Procaccio, V.; Reynier, P.; Ferre, M., A locus-specific database for mutations in GDAP1 allows analysis of genotype-phenotype correlations in Charcot-Marie-Tooth diseases type 4A and 2K. *Orphanet journal of rare diseases* **2011**, 6, 87.
42. Niemann, A.; Ruegg, M.; La Padula, V.; Schenone, A.; Suter, U., Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease. *The Journal of cell biology* **2005**, 170, (7), 1067-78.
43. Hakomori, S.; Igarashi, Y., Functional role of glycosphingolipids in cell recognition and signaling. *Journal of biochemistry* **1995**, 118, (6), 1091-103.
44. Modregger, J.; Schmidt, A. A.; Ritter, B.; Huttner, W. B.; Plomann, M., Characterization of Endophilin B1b, a brain-specific membrane-associated lysophosphatidic acid acyl transferase with properties distinct from endophilin A1. *The Journal of biological chemistry* **2003**, 278, (6), 4160-7.
45. Hinshaw, J. E., Dynamin and its role in membrane fission. *Annual review of cell and developmental biology* **2000**, 16, 483-519.



46. Schmidt, A.; Wolde, M.; Thiele, C.; Fest, W.; Kratzin, H.; Podtelejnikov, A. V.; Witke, W.; Huttner, W. B.; Soling, H. D., Endophilin I mediates synaptic vesicle formation by transfer of arachidonate to lysophosphatidic acid. *Nature* **1999**, 401, (6749), 133-41.
47. Gad, H.; Ringstad, N.; Low, P.; Kjaerulff, O.; Gustafsson, J.; Wenk, M.; Di Paolo, G.; Nemoto, Y.; Crun, J.; Ellisman, M. H.; De Camilli, P.; Shupliakov, O.; Brodin, L., Fission and uncoating of synaptic clathrin-coated vesicles are perturbed by disruption of interactions with the SH3 domain of endophilin. *Neuron* **2000**, 27, (2), 301-12.
48. Huttner, W. B.; Schmidt, A., Lipids, lipid modification and lipid-protein interaction in membrane budding and fission—insights from the roles of endophilin A1 and synaptophysin in synaptic vesicle endocytosis. *Current opinion in neurobiology* **2000**, 10, (5), 543-51.
49. Cuddeback, S. M.; Yamaguchi, H.; Komatsu, K.; Miyashita, T.; Yamada, M.; Wu, C.; Singh, S.; Wang, H. G., Molecular cloning and characterization of Bif-1. A novel Src homology 3 domain-containing protein that associates with Bax. *The Journal of biological chemistry* **2001**, 276, (23), 20559-65.
50. Takahashi, Y.; Karbowski, M.; Yamaguchi, H.; Kazi, A.; Wu, J.; Sebt, S. M.; Youle, R. J.; Wang, H. G., Loss of Bif-1 suppresses Bax/Bak conformational change and mitochondrial apoptosis. *Molecular and cellular biology* **2005**, 25, (21), 9369-82.
51. Karbowski, M.; Jeong, S. Y.; Youle, R. J., Endophilin B1 is required for the maintenance of mitochondrial morphology. *The Journal of cell biology* **2004**, 166, (7), 1027-39.
52. Takahashi, Y.; Coppola, D.; Matsushita, N.; Cialing, H. D.; Sun, M.; Sato, Y.; Liang, C.; Jung, J. U.; Cheng, J. Q.; Mule, J. J.; Pledger, W. J.; Wang, H. G., Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. *Nature cell biology* **2007**, 9, (10), 1142-51.
53. Scorrano, L., Keeping mitochondria in shape: a matter of life and death. *European journal of clinical investigation* **2013**, 43, (8), 886-93.
54. Malka, F.; Guillery, O.; Cifuentes-Diaz, C.; Guillou, E.; Belenguer, P.; Lombes, A.; Rojo, M., Separate fusion of outer and inner mitochondrial membranes. *EMBO reports* **2005**, 6, (9), 853-9.
55. Song, Z.; Ghochani, M.; McCaffery, J. M.; Frey, T. G.; Chan, D. C., Mitofusins and OPA1 mediate sequential steps in mitochondrial membrane fusion. *Molecular biology of the cell* **2009**, 20, (15), 3525-32.
56. Olichon, A.; Emorine, L. J.; Descoins, E.; Pelloquin, L.; Brichese, L.; Gas, N.; Guillou, E.; Delettre, C.; Valette, A.; Hamel, C. P.; Ducommun, B.; Lenaers, G.; Belenguer, P., The human dynamin-related protein OPA1 is anchored to the mitochondrial inner membrane facing the inter-membrane space. *FEBS letters* **2002**, 523, (1-3), 171-6.
57. Mozdy, A. D.; Shaw, J. M., A fuzzy mitochondrial fusion apparatus comes into focus. *Nature reviews. Molecular cell biology* **2003**, 4, (6), 468-78.
58. de Brito, O. M.; Scorrano, L., Mitofusin 2: a mitochondria-shaping protein with signaling roles beyond fusion. *Antioxidants & redox signaling* **2008**, 10, (3), 621-33.
59. Bourne, H. R.; Sanders, D. A.; McCormick, F., The GTPase superfamily: conserved structure and molecular mechanism. *Nature* **1991**, 349, 117.
60. Chen, H.; McCaffery, J. M.; Chan, D. C., Mitochondrial fusion protects against neurodegeneration in the cerebellum. *Cell* **2007**, 130, (3), 548-62.
61. Ishihara, N.; Eura, Y.; Mihara, K., Mitofusin 1 and 2 play distinct roles in mitochondrial fusion reactions via GTPase activity. *Journal of cell science* **2004**, 117, (Pt 26), 6535-46.
62. Mishra, P.; Carelli, V.; Manfredi, G.; Chan, D. C., Proteolytic cleavage of Opa1 stimulates mitochondrial inner membrane fusion and couples fusion to oxidative phosphorylation. *Cell metabolism* **2014**, 19, (4), 630-41.
63. Griparic, L.; van der Wel, N. N.; Orozco, I. J.; Peters, P. J.; van der Bliek, A. M., Loss of the intermembrane space protein Mgm1/OPA1 induces swelling and localized constrictions along the lengths of mitochondria. *The Journal of biological chemistry* **2004**, 279, (18), 18792-8.
64. Ehses, S.; Raschke, I.; Mancuso, G.; Bernacchia, A.; Geimer, S.; Tondera, D.; Martinou, J. C.; Westermann, B.; Rugarli, E. I.; Langer, T., Regulation of OPA1 processing and mitochondrial fusion by m-AAA protease isoenzymes and OMA1. *The Journal of cell biology* **2009**, 187, (7), 1023-36.
65. Head, B.; Griparic, L.; Amiri, M.; Gandre-Babbe, S.; van der Bliek, A. M., Inducible proteolytic inactivation of OPA1 mediated by the OMA1 protease in mammalian cells. *The Journal of cell biology* **2009**, 187, (7), 959-66.



66. Rabl, R.; Soubannier, V.; Scholz, R.; Vogel, F.; Mendl, N.; Vasiljev-Neumeyer, A.; Korner, C.; Jagasia, R.; Keil, T.; Baumeister, W.; Cyrklaff, M.; Neupert, W.; Reichert, A. S., Formation of cristae and crista junctions in mitochondria depends on antagonism between Fcjl and Su e/g. *The Journal of cell biology* **2009**, 185, (6), 1047-63.
67. Cogliati, S.; Frezza, C.; Soriano, M. E.; Varanita, T.; Quintana-Cabrera, R.; Corrado, M.; Cipolat, S.; Costa, V.; Casarin, A.; Gomes, L. C.; Perales-Clemente, E.; Salviati, L.; Fernandez-Silva, P.; Enriquez, J. A.; Scorrano, L., Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency. *Cell* **2013**, 155, (1), 160-71.
68. Lazarou, M.; Sliter, D. A.; Kane, L. A.; Sarraf, S. A.; Wang, C.; Burman, J. L.; Sideris, D. P.; Fogel, A. I.; Youle, R. J., The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. *Nature* **2015**, 524, (7565), 309-314.
69. Narendra, D. P.; Jin, S. M.; Tanaka, A.; Suen, D.-F.; Gautier, C. A.; Shen, J.; Cookson, M. R.; Youle, R. J., PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin. *PLOS Biology* **2010**, 8, (1), e1000298.
70. Dorn, G. W., 2nd; Kitsis, R. N., The mitochondrial dynamism-mitophagy-cell death interactome: multiple roles performed by members of a mitochondrial molecular ensemble. *Circulation research* **2015**, 116, (1), 167-82.
71. Youle, R. J.; Narendra, D. P., Mechanisms of mitophagy. *Nature Reviews Molecular Cell Biology* **2010**, 12, 9.
72. Chinta, S. J.; Andersen, J. K., Redox imbalance in Parkinson's disease. *Biochimica et biophysica acta* **2008**, 1780, (11), 1362-7.
73. Panicker, N.; Dawson, V. L.; Dawson, T. M., Activation mechanisms of the E3 ubiquitin ligase parkin. *The Biochemical journal* **2017**, 474, (18), 3075-3086.
74. Lazarou, M.; Sliter, D. A.; Kane, L. A.; Sarraf, S. A.; Wang, C.; Burman, J. L.; Sideris, D. P.; Fogel, A. I.; Youle, R. J., The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. *Nature* **2015**, 524, 309.
75. Jin, S. M.; Youle, R. J., PINK1- and Parkin-mediated mitophagy at a glance. *Journal of cell science* **2012**, 125, (Pt 4), 795-9.
76. Dagda, R. K.; Cherra, S. J., 3rd; Kulich, S. M.; Tandon, A.; Park, D.; Chu, C. T., Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. *The Journal of biological chemistry* **2009**, 284, (20), 13843-55.
77. Lutz, A. K.; Exner, N.; Fett, M. E.; Schlehe, J. S.; Kloos, K.; Lammermann, K.; Brunner, B.; Kurz-Drexler, A.; Vogel, F.; Reichert, A. S.; Bouman, L.; Vogt-Weisenhorn, D.; Wurst, W.; Tatzelt, J.; Haass, C.; Winklhofer, K. F., Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation. *The Journal of biological chemistry* **2009**, 284, (34), 22938-51.
78. Vance, J. E., MAM (mitochondria-associated membranes) in mammalian cells: lipids and beyond. *Biochimica et biophysica acta* **2014**, 1841, (4), 595-609.
79. Ernster, L.; Schatz, G., Mitochondria: a historical review. *The Journal of cell biology* **1981**, 91, (3 Pt 2), 227s-255s.
80. Chen, H.; Chan, D. C., Mitochondrial Dynamics in Regulating the Unique Phenotypes of Cancer and Stem Cells. *Cell metabolism* **2017**, 26, (1), 39-48.
81. Zick, M.; Rabl, R.; Reichert, A. S., Cristae formation-linking ultrastructure and function of mitochondria. *Biochimica et biophysica acta* **2009**, 1793, (1), 5-19.
82. Rossignol, R.; Gilkerson, R.; Aggeler, R.; Yamagata, K.; Remington, S. J.; Capaldi, R. A., Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. *Cancer research* **2004**, 64, (3), 985-93.
83. Collins, T. J.; Berridge, M. J.; Lipp, P.; Bootman, M. D., Mitochondria are morphologically and functionally heterogeneous within cells. *The EMBO journal* **2002**, 21, (7), 1616-27.
84. Zhou, W.; Choi, M.; Margineantu, D.; Margaretha, L.; Hesson, J.; Cavanaugh, C.; Blau, C. A.; Horwitz, M. S.; Hockenbery, D.; Ware, C.; Ruohola-Baker, H., HIF1alpha induced switch from bivalent to exclusively glycolytic metabolism during ESC-to-EpiSC/hESC transition. *The EMBO journal* **2012**, 31, (9), 2103-16.
85. Beckervordersandforth, R.; Ebert, B.; Schaffner, I.; Moss, J.; Fiebig, C.; Shin, J.; Moore, D. L.; Ghosh, L.; Trincherio, M. F.; Stockburger, C.; Friedland, K.; Steib, K.; von Wittgenstein, J.; Keiner, S.; Redecker, C.; Holter, S. M.; Xiang, W.; Wurst, W.; Jagasia, R.; Schinder, A. F.; Ming, G. L.; Toni, N.; Jessberger, S.; Song, H.; Lie, D. C., Role of Mitochondrial Metabolism in the Control of Early Lineage Progression and Aging Phenotypes in Adult Hippocampal Neurogenesis. *Neuron* **2017**, 93, (6), 1518.

86. Khacho, M.; Clark, A.; Svoboda, D. S.; Azzi, J.; MacLaurin, J. G.; Meghaizel, C.; Sesaki, H.; Lagace, D. C.; Germain, M.; Harper, M. E.; Park, D. S.; Slack, R. S., Mitochondrial Dynamics Impacts Stem Cell Identity and Fate Decisions by Regulating a Nuclear Transcriptional Program. *Cell stem cell* **2016**, *19*, (2), 232-247.
87. Chen, C. T.; Shih, Y. R.; Kuo, T. K.; Lee, O. K.; Wei, Y. H., Coordinated changes of mitochondrial biogenesis and antioxidant enzymes during osteogenic differentiation of human mesenchymal stem cells. *Stem cells* **2008**, *26*, (4), 960-8.
88. Simsek, T.; Kocabas, F.; Zheng, J.; Deberardinis, R. J.; Mahmoud, A. I.; Olson, E. N.; Schneider, J. W.; Zhang, C. C.; Sadek, H. A., The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. *Cell stem cell* **2010**, *7*, (3), 380-90.
89. Suda, T.; Takubo, K.; Semenza, G. L., Metabolic regulation of hematopoietic stem cells in the hypoxic niche. *Cell stem cell* **2011**, *9*, (4), 298-310.
90. Zheng, X.; Boyer, L.; Jin, M.; Mertens, J.; Kim, Y.; Ma, L.; Ma, L.; Hamm, M.; Gage, F. H.; Hunter, T., Metabolic reprogramming during neuronal differentiation from aerobic glycolysis to neuronal oxidative phosphorylation. *eLife* **2016**, *5*.
91. Forni, M. F.; Peloggia, J.; Trudeau, K.; Shirihai, O.; Kowaltowski, A. J., Murine Mesenchymal Stem Cell Commitment to Differentiation Is Regulated by Mitochondrial Dynamics. *Stem cells* **2016**, *34*, (3), 743-55.
92. Snoeck, H. W., Mitochondrial regulation of hematopoietic stem cells. *Current opinion in cell biology* **2017**, *49*, 91-98.
93. Luchsinger, L. L.; de Almeida, M. J.; Corrigan, D. J.; Mumau, M.; Snoeck, H. W., Mitofusin 2 maintains haematopoietic stem cells with extensive lymphoid potential. *Nature* **2016**, *529*, (7587), 528-31.
94. Warburg, O., On respiratory impairment in cancer cells. *Science* **1956**, *124*, (3215), 269-70.
95. Takahashi, K.; Yamanaka, S., Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* **2006**, *126*, (4), 663-76.
96. Vander Heiden, M. G.; Cantley, L. C.; Thompson, C. B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* **2009**, *324*, (5930), 1029-33.
97. Lisowski, P.; Kannan, P.; Mlody, B.; Prigione, A., Mitochondria and the dynamic control of stem cell homeostasis. *EMBO reports* **2018**, *19*, (5).
98. Zhang, J.; Khvorostov, I.; Hong, J. S.; Oktay, Y.; Vergnes, L.; Nuebel, E.; Wahjudi, P. N.; Setoguchi, K.; Wang, G.; Do, A.; Jung, H. J.; McCaffery, J. M.; Kurland, I. J.; Reue, K.; Lee, W. N.; Koehler, C. M.; Teitell, M. A., UCP2 regulates energy metabolism and differentiation potential of human pluripotent stem cells. *The EMBO journal* **2011**, *30*, (24), 4860-73.
99. Voza, A.; Parisi, G.; De Leonardi, F.; Lasorsa, F. M.; Castegna, A.; Amorese, D.; Marmo, R.; Calcagnile, V. M.; Palmieri, L.; Ricquier, D.; Paradies, E.; Scarcia, P.; Palmieri, F.; Bouillaud, F.; Fiermonte, G., UCP2 transports C4 metabolites out of mitochondria, regulating glucose and glutamine oxidation. *Proceedings of the National Academy of Sciences of the United States of America* **2014**, *111*, (3), 960-5.
100. Zhang, H.; Badur, M. G.; Divakaruni, A. S.; Parker, S. J.; Jager, C.; Hiller, K.; Murphy, A. N.; Metallo, C. M., Distinct Metabolic States Can Support Self-Renewal and Lipogenesis in Human Pluripotent Stem Cells under Different Culture Conditions. *Cell reports* **2016**, *16*, (6), 1536-1547.
101. Choi, H. W.; Kim, J. H.; Chung, M. K.; Hong, Y. J.; Jang, H. S.; Seo, B. J.; Jung, T. H.; Kim, J. S.; Chung, H. M.; Byun, S. J.; Han, S. G.; Seo, H. G.; Do, J. T., Mitochondrial and metabolic remodeling during reprogramming and differentiation of the reprogrammed cells. *Stem cells and development* **2015**, *24*, (11), 1366-73.
102. Prigione, A.; Fauler, B.; Lurz, R.; Lehrach, H.; Adjaye, J., The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells. *Stem cells* **2010**, *28*, (4), 721-33.
103. Suhr, S. T.; Chang, E. A.; Tjong, J.; Alcasid, N.; Perkins, G. A.; Goissis, M. D.; Ellisman, M. H.; Perez, G. I.; Cibelli, J. B., Mitochondrial rejuvenation after induced pluripotency. *PloS one* **2010**, *5*, (11), e14095.
104. Folmes, C. D.; Nelson, T. J.; Martinez-Fernandez, A.; Arrell, D. K.; Lindor, J. Z.; Dzeja, P. P.; Ikeda, Y.; Perez-Terzic, C.; Terzic, A., Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. *Cell metabolism* **2011**, *14*, (2), 264-71.
105. Vazquez-Martin, A.; Cufi, S.; Corominas-Faja, B.; Oliveras-Ferraro, C.; Vellon, L.; Menendez, J. A., Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: new insight into the role of mitophagy in cell stemness. *Aging* **2012**, *4*, (6), 393-401.
106. Son, M. Y.; Choi, H.; Han, Y. M.; Cho, Y. S., Unveiling the critical role of REX1 in the regulation of human stem cell pluripotency. *Stem cells* **2013**, *31*, (11), 2374-87.

107. Serasinghe, M. N.; Wieder, S. Y.; Renault, T. T.; Elkholi, R.; Asciolla, J. J.; Yao, J. L.; Jabado, O.; Hoehn, K.; Kageyama, Y.; Sesaki, H.; Chipuk, J. E., Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors. *Molecular cell* **2015**, *57*, (3), 521-36.
108. Prieto, J.; Leon, M.; Ponsoda, X.; Sendra, R.; Bort, R.; Ferrer-Lorente, R.; Raya, A.; Lopez-Garcia, C.; Torres, J., Early ERK1/2 activation promotes DRP1-dependent mitochondrial fission necessary for cell reprogramming. *Nature communications* **2016**, *7*, 11124.
109. Prieto, J.; Leon, M.; Ponsoda, X.; Garcia-Garcia, F.; Bort, R.; Serna, E.; Barneo-Munoz, M.; Palau, F.; Dopazo, J.; Lopez-Garcia, C.; Torres, J., Dysfunctional mitochondrial fission impairs cell reprogramming. *Cell cycle* **2016**, *15*, (23), 3240-3250.
110. Son, M. J.; Kwon, Y.; Son, M. Y.; Seol, B.; Choi, H. S.; Ryu, S. W.; Choi, C.; Cho, Y. S., Mitofusins deficiency elicits mitochondrial metabolic reprogramming to pluripotency. *Cell death and differentiation* **2015**, *22*, (12), 1957-69.
111. Yanes, O.; Clark, J.; Wong, D. M.; Patti, G. J.; Sanchez-Ruiz, A.; Benton, H. P.; Trauger, S. A.; Despons, C.; Ding, S.; Siuzdak, G., Metabolic oxidation regulates embryonic stem cell differentiation. *Nature chemical biology* **2010**, *6*, (6), 411-7.
112. Wakabayashi, J.; Zhang, Z.; Wakabayashi, N.; Tamura, Y.; Fukaya, M.; Kensler, T. W.; Iijima, M.; Sesaki, H., The dynamin-related GTPase Drp1 is required for embryonic and brain development in mice. *The Journal of cell biology* **2009**, *186*, (6), 805-16.
113. Ishihara, N.; Nomura, M.; Jofuku, A.; Kato, H.; Suzuki, S. O.; Masuda, K.; Otera, H.; Nakanishi, Y.; Nonaka, I.; Goto, Y.; Taguchi, N.; Morinaga, H.; Maeda, M.; Takayanagi, R.; Yokota, S.; Mihara, K., Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. *Nature cell biology* **2009**, *11*, (8), 958-66.
114. Manczak, M.; Sesaki, H.; Kageyama, Y.; Reddy, P. H., Dynamin-related protein 1 heterozygote knockout mice do not have synaptic and mitochondrial deficiencies. *Biochimica et biophysica acta* **2012**, *1822*, (6), 862-74.
115. Kim, H. J.; Shaker, M. R.; Cho, B.; Cho, H. M.; Kim, H.; Kim, J. Y.; Sun, W., Dynamin-related protein 1 controls the migration and neuronal differentiation of subventricular zone-derived neural progenitor cells. *Scientific reports* **2015**, *5*, 15962.
116. De Palma, C.; Falcone, S.; Pisoni, S.; Cipolat, S.; Panzeri, C.; Pambianco, S.; Pisconti, A.; Allevi, R.; Bassi, M. T.; Cossu, G.; Pozzan, T.; Moncada, S.; Scorrano, L.; Brunelli, S.; Clementi, E., Nitric oxide inhibition of Drp1-mediated mitochondrial fission is critical for myogenic differentiation. *Cell death and differentiation* **2010**, *17*, (11), 1684-96.
117. Kim, B.; Kim, J. S.; Yoon, Y.; Santiago, M. C.; Brown, M. D.; Park, J. Y., Inhibition of Drp1-dependent mitochondrial division impairs myogenic differentiation. *American journal of physiology. Regulatory, integrative and comparative physiology* **2013**, *305*, (8), R927-38.
118. Sin, J.; Andres, A. M.; Taylor, D. J. R.; Weston, T.; Hiraumi, Y.; Stotland, A.; Kim, B. J.; Huang, C.; Doran, K. S.; Gottlieb, R. A., Mitophagy is required for mitochondrial biogenesis and myogenic differentiation of C2C12 myoblasts. *Autophagy* **2016**, *12*, (2), 369-380.
119. Hoque, A.; Sivakumaran, P.; Bond, S. T.; Ling, N. X. Y.; Kong, A. M.; Scott, J. W.; Bandara, N.; Hernandez, D.; Liu, G. S.; Wong, R. C. B.; Ryan, M. T.; Hausenloy, D. J.; Kemp, B. E.; Oakhill, J. S.; Drew, B. G.; Pebay, A.; Lim, S. Y., Mitochondrial fission protein Drp1 inhibition promotes cardiac mesodermal differentiation of human pluripotent stem cells. *Cell death discovery* **2018**, *4*, 39.
120. Pei, S.; Minhajuddin, M.; Adane, B.; Khan, N.; Stevens, B. M.; Mack, S. C.; Lai, S.; Rich, J. N.; Inguva, A.; Shannon, K. M.; Kim, H.; Tan, A. C.; Myers, J. R.; Ashton, J. M.; Neff, T.; Pollyea, D. A.; Smith, C. A.; Jordan, C. T., AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. *Cell stem cell* **2018**, *23*, (1), 86-100 e6.
121. Kasahara, A.; Cipolat, S.; Chen, Y.; Dorn, G. W., 2nd; Scorrano, L., Mitochondrial fusion directs cardiomyocyte differentiation via calcineurin and Notch signaling. *Science* **2013**, *342*, (6159), 734-7.
122. Fang, D.; Yan, S.; Yu, Q.; Chen, D.; Yan, S. S., Mfn2 is Required for Mitochondrial Development and Synapse Formation in Human Induced Pluripotent Stem Cells/hiPSC Derived Cortical Neurons. *Scientific reports* **2016**, *6*, 31462.
123. Rizzuto, R.; De Stefani, D.; Raffaello, A.; Mammucari, C., Mitochondria as sensors and regulators of calcium signalling. *Nature Reviews Molecular Cell Biology* **2012**, *13*, 566.
124. Brookes, P. S.; Yoon, Y.; Robotham, J. L.; Anders, M. W.; Sheu, S. S., Calcium, ATP, and ROS: a mitochondrial love-hate triangle. *American journal of physiology. Cell physiology* **2004**, *287*, (4), C817-33.

125. Lynch, D. B.; Jeffery, I. B.; O'Toole, P. W., The role of the microbiota in ageing: current state and perspectives. *Wiley interdisciplinary reviews. Systems biology and medicine* **2015**, 7, (3), 131-8.
126. Shadyab, A. H.; LaCroix, A. Z., Genetic factors associated with longevity: a review of recent findings. *Ageing research reviews* **2015**, 19, 1-7.
127. Sergiev, P. V.; Dontsova, O. A.; Berezkin, G. V., Theories of aging: an ever-evolving field. *Acta naturae* **2015**, 7, (1), 9-18.
128. Mai, S.; Klinkenberg, M.; Auburger, G.; Bereiter-Hahn, J.; Jendrach, M., Decreased expression of Drp1 and Fis1 mediates mitochondrial elongation in senescent cells and enhances resistance to oxidative stress through PINK1. *Journal of cell science* **2010**, 123, (Pt 6), 917-26.
129. Lin, J. R.; Shen, W. L.; Yan, C.; Gao, P. J., Downregulation of dynamin-related protein 1 contributes to impaired autophagic flux and angiogenic function in senescent endothelial cells. *Arteriosclerosis, thrombosis, and vascular biology* **2015**, 35, (6), 1413-22.
130. Kim, Y. M.; Youn, S. W.; Sudhakar, V.; Das, A.; Chandhri, R.; Cuervo Grajal, H.; Kweon, J.; Leanhart, S.; He, L.; Toth, P. T.; Kitajewski, J.; Rehman, J.; Yoon, Y.; Cho, J.; Fukai, T.; Ushio-Fukai, M., Redox Regulation of Mitochondrial Fission Protein Drp1 by Protein Disulfide Isomerase Limits Endothelial Senescence. *Cell reports* **2018**, 23, (12), 3565-3578.
131. Leduc-Gaudet, J. P.; Picard, M.; St-Jean Pelletier, F.; Sgaroto, N.; Auger, M. J.; Vallee, J.; Robitaille, R.; St-Pierre, D. H.; Gouspillou, G., Mitochondrial morphology is altered in atrophied skeletal muscle of aged mice. *Oncotarget* **2015**, 6, (20), 17923-37.
132. Sebastian, D.; Sorianello, E.; Segales, J.; Irazoki, A.; Ruiz-Bonilla, V.; Sala, D.; Planet, E.; Berenguer-Llargo, A.; Munoz, J. P.; Sanchez-Feutrie, M.; Plana, N.; Hernandez-Alvarez, M. I.; Serrano, A. L.; Palacin, M.; Zorzano, A., Mfn2 deficiency links age-related sarcopenia and impaired autophagy to activation of an adaptive mitophagy pathway. *The EMBO journal* **2016**, 35, (15), 1677-93.
133. Lang, A.; Anand, R.; Altinolu-Hambuchen, S.; Ezzahoni, H.; Stefanski, A.; Iram, A.; Bergmann, L.; Urbach, J.; Bohler, P.; Hansel, J.; Franke, M.; Stuhler, K.; Krutmann, J.; Scheller, J.; Stork, B.; Reichert, A. S.; Piekorz, R. P., SIRT4 interacts with OPA1 and regulates mitochondrial quality control and mitophagy. *Aging* **2017**, 9, (10), 2163-2189.
134. Parasuraman, R.; Greenwood, P. M.; Alexander, G. E., Alzheimer disease constricts the dynamic range of spatial attention in visual search. *Neuropsychologia* **2000**, 38, (8), 1126-35.
135. Delettre, C.; Lenaers, G.; Griffoin, J. M.; Gigarel, N.; Lorenzo, C.; Belenguer, P.; Pelloquin, L.; Grosgeorge, J.; Turc-Carel, C.; Perret, E.; Astarie-Dequeker, C.; Lasquelllec, L.; Arnaud, B.; Ducommun, B.; Kaplan, J.; Hamel, C. P., Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. *Nature genetics* **2000**, 26, (2), 207-10.
136. Cuesta, A.; Pedrola, L.; Sevilla, T.; Garcia-Planells, J.; Chumillas, M. J.; Mayordomo, F.; LeGuern, E.; Marin, I.; Vilchez, J. J.; Palau, F., The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease. *Nature genetics* **2002**, 30, (1), 22-5.
137. Waterham, H. R.; Koster, J.; van Roermund, C. W.; Mooyer, P. A.; Wanders, R. J.; Leonard, J. V., A lethal defect of mitochondrial and peroxisomal fission. *The New England journal of medicine* **2007**, 356, (17), 1736-41.
138. Deng, H.; Le, W.; Shahed, J.; Xie, W.; Jankovic, J., Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families. *Neuroscience letters* **2008**, 430, (1), 18-22.
139. Yang, X.; Yang, Y.; Li, G.; Wang, J.; Yang, E. S., Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. *Journal of molecular neuroscience : MN* **2008**, 34, (2), 165-71.